Assertio (ASRT)
(Delayed Data from NSDQ)
$0.71 USD
0.00 (0.11%)
Updated Aug 4, 2025 12:33 PM ET
3-Hold of 5 3
A Value F Growth F Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
Currently, Assertio Holdings, Inc. has a PEG ratio of 0.97 compared to the Medical - Drugs industry's PEG ratio of 1.08.
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ASRT 0.71 0.00(0.11%)
Will ASRT be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ASRT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ASRT
New Strong Sell Stocks for July 8th
New Strong Sell Stocks for June 30th
ASRT: What are Zacks experts saying now?
Zacks Private Portfolio Services
New Strong Sell Stocks for June 25th
New Strong Sell Stocks for June 18th
Assertio (ASRT) Reports Q1 Loss, Misses Revenue Estimates
Other News for ASRT
Assertio Holdings (ASRT) Receives Reiterated Buy Rating with $3.50 Price Target | ASRT Stock News
Assertio Therapeutics: Buy Rating Affirmed Amid Strong ROLVEDON Growth and Positive Financial Outlook
Assertio to Participate in the Alliance Global Partners Healthcare Company Showcase on May 21, ...
Assertio Therapeutics’ Earnings Call: Mixed Results and Strategic Plans
Maxim Group Sticks to Its Buy Rating for Assertio Therapeutics (ASRT)